SXTP vs. ALLR, SNOA, CWBR, SLRX, DRMA, CYTO, BPTSY, ATXI, CNSP, and VRPX
Should you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include Allarity Therapeutics (ALLR), Sonoma Pharmaceuticals (SNOA), CohBar (CWBR), Salarius Pharmaceuticals (SLRX), Dermata Therapeutics (DRMA), Altamira Therapeutics (CYTO), Biophytis (BPTSY), Avenue Therapeutics (ATXI), CNS Pharmaceuticals (CNSP), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical preparations" industry.
Allarity Therapeutics (NASDAQ:ALLR) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability.
60 Degrees Pharmaceuticals has a consensus target price of $2.40, indicating a potential upside of 998.40%. Given Allarity Therapeutics' higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Allarity Therapeutics.
11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 0.0% of Allarity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Allarity Therapeutics and 60 Degrees Pharmaceuticals both received 1 outperform votes by MarketBeat users. However, 50.00% of users gave Allarity Therapeutics an outperform vote while only 33.33% of users gave 60 Degrees Pharmaceuticals an outperform vote.
In the previous week, Allarity Therapeutics had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 5 mentions for Allarity Therapeutics and 4 mentions for 60 Degrees Pharmaceuticals. Allarity Therapeutics' average media sentiment score of 1.23 beat 60 Degrees Pharmaceuticals' score of 0.68 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.
60 Degrees Pharmaceuticals has higher revenue and earnings than Allarity Therapeutics.
Summary
60 Degrees Pharmaceuticals beats Allarity Therapeutics on 6 of the 10 factors compared between the two stocks.
Get 60 Degrees Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
60 Degrees Pharmaceuticals Competitors List
Related Companies and Tools
